Top Targeted Protein Degradation Companies
.png)
Published: July 2024
Targeted protein degradation has revolutionized the field of protein degradation and protein homeostasis by offering several advanced protein degraders and treatment options.Targeted protein degradation has revolutionized the field of protein degradation and protein homeostasis by offering several advanced protein degraders and treatment options.
Protein degradation plays a vital role in maintaining protein equilibrium in the human body. In general, small molecule inhibitors, antisense oligonucleotides and monoclonal antibodies were utilized for protein degradation that binds to the specific pathogenic proteins to hinder their activity to obtain therapeutic results. However, the existing inhibitors bind to constricted pathogenic agents, comprising less than 20% of all disease-causing proteins, leaving 80% of them as undruggable targets. This limitation has paved the way for the development of targeted protein degradation approaches. Targeted protein degradation is a novel drug discovery approach that leads to destruction of disease-causing proteins by hijacking cellular machinery within the small molecules. This modality responsible for degradation of proteins is known as protein degraders. Protein degraders are bifunctional small molecules that recruit E3 ubiquitin ligases to the protein of interest and mediate its ubiquitination and subsequent proteolysis by the proteasome.
Roots Analysis has conducted an exhaustive study on Targeted Protein Degradation Market featuring the current market landscape and future opportunity for the companies engaged in offering targeted protein degradation therapeutics, over a span of 11 years.
Table of Contents
Below, we have listed (in alphabetical order), the top eight targeted protein degradation companies:
- Arvinas
- AstraZeneca
- Bristol-Myers Squibb
- C4 Therapeutics
- Loxo Oncology
- Olema Oncology
- Radius Health
- Roche
Interested in exploring all 90+ Targeted Protein Degradation Companies and their recent initiatives?
Discover Below the Details on 8 Top Targeted Protein Degradation Companies
Let us deep dive to understand the activity of the 8 top targeted protein degradation companies (companies with advanced pipeline) in the targeted protein degradation market. It is essential to note that the selection of top players can differ substantially according to the defined criteria.
Arvinas Holds a Rich Pipeline of Protein Degraders, With its Lead Molecule Receiving Fast Track Status
1. Arvinas
Arvinas is a US-based clinical-stage biopharmaceutical company with a primary focus on the discovery and development of innovative therapies for various diseases. The company leverages its proprietary Proteolysis Targeting Chimeras (PROTAC) platform for the selective removal of disease-causing proteins. In addition, the firm has a robust pipeline of pre-clinical and clinical targeted protein degardation therapeutics that has the potential to eliminate “undruggable” targets, which was not possible with conventional protein inhibitors.
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 2013 |
| Number of Employees | 201-500 |
| Headquarter |  |
Recent Developments:
In April 2024, the company inked a partnership with Novartis for its phase I/II stage drug ARV-766 for treatment of metastatic castration-resistant prostate cancer. Under the terms of the agreement, Arvinas stands to receive an upfront payment of $150 million with up to $ 1.01 billion in milestone payments and royalties.
In February 2024, the company lead phase III molecule, ARV-471 / Vepdegestrant, received fast track status from the FDA for treatment of adults with ER+/HER2- locally advanced or metastatic breast cancer.
Further details on Arvinas’ pipeline and other targeted protein degradation companies have been provided in detail in the report.
AstraZeneca, Evaluating its Protein Degrader for both Monotherapy and Combination Therapy
2. AstraZeneca
AstraZeneca is a patient-centric pharmaceutical company specializing in the development of advanced modalities, such as biologics, cell therapies and nucleotide-based therapeutics. Moreover, the company aims to deliver innovative, precise, and personalized solutions across various therapeutic areas, such as oncology, immunology, respiratory, cardiovascular and others. It is worth noting that the firm has a diverse portfolio of medications, including targeted protein degraders. The firm is primarily engaged in the development of PROTACs and molecular glues along with the suite of pharmacology and safety assays to monitor protein degradation and disease efficacy.
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 1999 |
| Number of Employees | 10,001+ |
| Headquarter |  |
Recent Developments:
In 2023, AstraZeneca virtually presented data on therapies focused on cancer, including Camizestrant at the American Society of Clinical Oncology (ASCO) Annual Meeting. Camizestrant is currently being evaluated as combination therapy in phase III and monotherapy in phase II clinical trials targeting various forms of breast cancer.
Further details on AstraZeneca’s pipeline and other targeted protein degradation companies have been provided in detail in the report.
Bristol Myers Squibb is Evaluating the Potential of Artificial Intelligence in Targeted Protein Degradation Market
3. Bristol-Myers Squibb
Bristol-Myers Squibb is a global pharmaceutical company focused on tranforming the lives of patients, globally by researching, developing and manufacturing innovative solutions for the treatment of various diseases. The company has built a sustainable pipeline of potential therapies by leveraging translational medicine and data analytics to provide tailored solutions and positive pateint outcomes. In addition, the company is significantly contributing towards the domain of targeted protein degardation by continously investigating protein degarders across different stages of development.
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 1887 |
| Number of Employees | 10,000+ |
| Headquarter |  |
Recent Developments:
In February 2024, the company partnered with VantAI to evaluate its generative AI platform for discovery of molecular glue degraders.
In January 2024, BMS presented data on BMS-986365 (targeted protein degrader) at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium, held in California, US.
Further details on Bristol-Myers Squibb’s pipeline and other targeted protein degradation companies have been provided in detail in the report.
C4 Therapeutics, Looking Forward to an Active 2024, with Several Trial Activities Planned
4. C4 Therapeutics
C4 Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of next-generation small molecule therapeutics. The company employs its proprietary TORPEDO platform to selectively target disease-causing proteins with the help of small heterobifunctional molecules. It is worth noting that the firm primarily focuses on the development of catalytically efficient degraders that can utilize cereblon E3 ligases for greater therapeutic effect.
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 2016 |
| Number of Employees | 51-200 |
| Headquarter |  |
Recent Developments:
During 2024, the company expects to present clinical data from phase I trials of its drug Cemsidomide
(CFT7455). For its second drug candidate CFT1946, C4 Therapeutics plans to present data from phase I dose escalation study in 2H 2024. Additionally, the company will be supporting its partner Betta Pharmaceuticals to initiate a phase I trial for CFT8919 in China during 2024.
In 2023, C4 Therapeutics collaborated with Merck for the development of Degrader-Antibody Conjugates (DACs) as novel cancer therapeutics.
Further details on C4 Therapeutics’ pipeline and other targeted protein degradation companies have been provided in detail in the report.
Loxo Oncology Participated in Events, Such as ASCO Annual Meeting and AACR Annual Meeting to Showcase the Efficacy Data of their Drug Imlunestrant®
5. Loxo Oncology
Loxo Oncology (a subsidiary of Eli Lily and Company) is a pharmaceutical company that caters to the unmet needs in the field of cancer. Therefore, the firm primarily focuses on identifying the right target, building a rational design and study right population to develop the best possible targeted protein degrader. In fact, the firm is investigating its lead candidate, Imlunestrant across various indications, such as breast cancer and hepatic impairment.
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 2013 |
| Number of Employees | 501-1,000 |
| Headquarter |  |
Further details on Loxo Oncology’s pipeline and other targeted protein degradation companies have been provided in detail in the report.
Olema Oncology is Focused on the Development of Palazestrant / OP-1250, its Lead Molecule in Phase III Clinical Trials
6. Olema Oncology
Olema Oncology specializes in the discovery and development of targeted therapies for cancers affecting women. The firm aims to address the challenges associated with existing therapies for ER+ breast cancer and is generating data to aid the development of next generation therapeutics. In order to do so, the company is investigating its lead program, palazestrant (OP-1250) that has combined ability of an estrogen receptor antagonist and selective estrogen receptor degrader, helping it to produce deeper anti-tumor effect.
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 2007 |
| Number of Employees | 51-200 |
| Headquarter |  |
Recent Developments:
In 2023, Olema Oncology presented data on OP-1250 (targeted protein degrader) at the 2023 ESMO Breast Cancer Annual Congress, held in Berlin, Germany. The drug is being evaluated in phase III clinical trials as a single agent; however, the company is also evaluating its efficacy as a combination therapy in phase I/II clinical trials.
Further details on Olema Oncology’s pipeline and other targeted protein degradation companies have been provided in detail in the report.
Radius Health Contributed to the Development of a Recently Approved SERD
7. Radius Health
Radius Health is a global biopharmaceutical company specializing in the development of therapies that can address unmet clinical needs in the field of bone health. Additionally, the firm also focuses on the development of targeted protein degraders.
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 2003 |
| Number of Employees | 201-500 |
| Headquarter |  |
Recent Developments:
Radius Health’s lead candidate elacestrant, which was developed in collaboration with Menarini Group received approval from FDA for the treatment of ER+, HER2- and ESR1-mutated advanced or metastatic breast cancer In January 2023. The drug is marketed under the brand name ORSERDUTM.
Further details on Radius Health and other targeted protein degradation companies have been provided in detail in the report.
Roche and its Subsidiary Genentech Have Also Explored the Collaboration Path for Foraying into Molecular Glue Degraders Development
8. Roche
Roche is a Swiss healthcare company with over 125 years of experience in development of innovative solutions across various therapeutics areas, including oncology, neurology, inflammatory, ophthalmology and several others. Moreover, the firm is dedicated to offer personalized healthcare leveraging its pharmaceutical and diagnostic capabilities for the development of targeted and effective therapies. It is worth noting that the firm has also recognized the potential of targeted protein degraders and is actively evaluating its degrader candidate for several oncological indications.
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 1896 |
| Number of Employees | 10,000+ |
| Headquarter |  |
Recent Developments:
In September 2023, Genentech collaborated with Orionis Biosciences with an aim to collaborate on the development of targeted protein degradation therapeutics against cancer and neurodegenerative disorders. This collaboration was preceded by its collaboration with Jemincare in August 2022.
In 2023, Roche presented data on Giredestrant®, its lead molecular glue degrader in phase III clinical trials, at the ESMO 2023, held in Madrid, Spain
Further details on Roche’s pipeline and other targeted protein degradation companies have been provided in detail in the report.
What About the Other Targeted Protein Degradation Companies Around the World?
The above presentation features eight top Targeted Protein Degradation Companies selected from a pool of over 90 players that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis.
Sources
https://www.pfizer.com/news/announcements/arvinas-and-pfizers-vepdegestrant-arv-471-receives-fda-fast-track-designation
https://www.astrazeneca.com/our-therapy-areas/pipeline.html
https://www.contractpharma.com/contents/view_breaking-news/2024-02-14/vantai-bms-partner-to-accelerate-molecular-glue-drug-discovery/
https://ir.c4therapeutics.com/static-files/f896dd2f-ad89-482d-8aa5-fb758a5812b0
https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06
https://radiuspharm.com/stemline-therapeutics-inc-receives-approval-from-u-s-fda-for-orserdutm-elacestrant-as-the-first-and-only-treatment-specifically-indicated-for-patients-with-esr1-mutations-in-er-her2-advanced-or/
https://www.fiercebiotech.com/biotech/chinas-jemincare-nabs-650m-biobucks-pact-roches-genentech-prostate-cancer-hopeful